SCHEMBL15905345

SCHEMBL15905345

CCN1c2cc(OCc3cccc(F)c3F)nc(=O)n2CCC1C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 10/20 0.46
PDE4A P27815 2/20 0.44
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GLP1R P43220 1/20 0.37
P2RX7 Q99572 1/20 0.37
CXCR2 P25025 1/20 0.34
ALKBH1 Q13686 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
IGF1R P08069 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15905344 1.00 GPR84 (0.46) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL17300372 0.91 GPR84 (0.46) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL15909921 0.88 GPR84 (0.48) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL15904778 0.88 GPR84 (0.48) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL15904780 0.88 GPR84 (0.48) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL15905221 0.86 GPR84 (0.46) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL15905222 0.86 GPR84 (0.46) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL15904949 0.86 GPR84 (0.40) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL15904948 0.86 GPR84 (0.40) GPR84PDE4AKDM4EALDH1A1GAA
SCHEMBL17300371 0.84 GPR84 (0.39) GPR84PDE4AKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150344485-A1 BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-12-03 US disclosed
EP-2948456-A1 BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 GlaxoSmithKline Intellectual Property Development Limited (GB) 2015-12-02 EP disclosed
WO-2014114249-A1 BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344485-A1 BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 PLA2G4A, PLA2G7, PLA2G6 GPR84 972/4885PDE4A 329/4885KDM4E 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.